Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis.

Authors: Longqi Chen, Yongde Liao, Xiaolong Yan, Mingqiang Kang, Xinyu Mei, Lijie Tan, Junfeng Liu, Zhang Zhang, Lei Liang, Alysha Kadva, Hongjing Jiang

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.4027

Source: Full article

---

Abstract

4027